Release Date: August 15, 2025
Expiration Date: August 15, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells while reducing off-target effects. In this activity, two experts in TNBC management discuss the rationales for using ADCs and the benefits of targeting TROP2 in this disease state.
Target Audience
This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care providers who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanistic rationale for utilizing ADCs to target TROP2 in the management of patients with metastatic TNBC
- Evaluate recent evidence supporting the evolving role of ADCs in the management of patients with metastatic TNBC
Filipa Lynce, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Inflammatory Breast Center
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Adviser: AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer; Grant/Research Funding: AstraZeneca, Gilead, IDEAYA, Incyte, Merck, Zentalis; Executive Role: Alliance Foundation Trials.
Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago Medicine
Chicago, IL
Disclosures: Advisory Board: Arvinas, AstraZeneca, Daiichi Sankyo, Exact Sciences, GE, Gilead, Guardant Health, Lilly, Merck, Moderna, Novartis, OBI, Pfizer, Sanofi, Seagen, Stemline, Summit Therapeutics; Research Funding: Arvinas, AstraZeneca, Bristol Myers Squibb, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.